心筋線維症:メカニズムとモデルから医薬品まで
Wenqiang Liu1, Xuekun Wu1, Wenshu Zeng1
1Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Trends in pharmacological sciences
|August 28, 2025
まとめ
心臓疾患の重要な特徴である 心臓線維症は 標的治療法がない 先進的なモデルを用いた新しい研究により 精度の高い抗線維治療の新たな動機と 治療戦略が明らかになりました
科学分野:
- 心臓病科
- 生物医学工学
- 幹細胞生物学
背景:
- 心筋線維症は,様々な心血管および全身疾患における重要な病理的特徴である.
- 心筋線維症の現在の治療戦略は限られており,直接線維性改造を標的とするFDAが承認した治療法はありません.
- 疾患モデリングと翻訳における課題は,効果的な抗線維治療の開発を妨げています.
研究 の 目的:
- 心筋線維症を誘発する新興の分子メカニズムを 検討する
- 心筋線維症の研究のための実験モデルにおける最近の進歩を統合する.
- 抗線維菌剤の臨床前および臨床試験の結果を統合する.
主な方法:
- 心筋線維症のメカニズムと治療開発に関する最近の文献の分析.
- 人間の誘発性多能幹細胞 (iPSC) 派生モデル,人工心臓組織,および体内システムに焦点を当てます.
- 分子ドライバと治療目標の文脈間調整を強調する.
主要な成果:
- 免疫ストロマのクロストラック,代謝再プログラム,メカニカルトランスデュークションを含む新しい線維性ドライバの特定.
- 実験モデルの進歩は,繊維の過程を研究するための信頼性を向上させます.
- 新興の抗線維薬は,臨床前および臨床試験で有望であることが示されています.
結論:
- 心筋線維症の治療方法の 発展に新たな洞察が 与えられています
- 先進的なモデルは 心筋線維症の理解と標的化に不可欠です
- 準確な抗線維治療の開発には 文脈間の調整が不可欠です
関連する概念動画
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:30Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
27
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
27